Regulatory Approval (ANDA)
Caplin Steriles Receives USFDA Approval for Foscarnet Sodium Injection
NSE
caplipoint
BSE
524742
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has received final USFDA approval for its ANDA Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), strengthening the company’s injectable portfolio in the regulated US market.
PRICE-SENSITIVE TRIGGER
Event: USFDA Final Approval for ANDA Product
Type: Regulatory Approval (ANDA)
Impact: Positive
Immediate Effect: The approval enables Caplin Steriles to market Foscarnet Sodium Injection in the US market, expanding its injectable product offerings and strengthening regulated market presence.
Key Metrics:
- Approved Product: Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag)
- US Market Size: Approximately US$15 million for 12 months ending March 2026
- US ANDAs Filed by CSL: 54 ANDAs
- Total ANDA Approvals: 55 approvals including acquired ANDAs
- Injectable & Ophthalmic Pipeline: 55+ products planned over next 4 years
Highlight:
- USFDA Final Approval Received for Foscarnet Sodium Injection
What Happened ?
Caplin Steriles Limited (CSL), a subsidiary of Caplin Point Laboratories Limited, announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Foscarnet Sodium Injection.
The approved product is therapeutically equivalent to the reference listed drug Foscarvir Injection from Clinigen Healthcare Ltd. The drug is primarily used for treatment of CMV retinitis in AIDS patients and HSV infections in immunocompromised individuals.
key highlights
Product & Regulatory Update:
- USFDA granted final approval for Foscarnet Sodium Injection.
- The product is supplied in a 6000 mg/250 mL infusion bag format.
- The injectable targets antiviral therapeutic applications.
- The US market opportunity for the product is estimated at approximately US$15 million annually.
- CSL continues expanding its regulated market injectable portfolio.
Caplin Steriles Growth Pipeline:
- CSL has filed 54 ANDAs in the US market.
- Total approvals currently stand at 55 including acquired approvals.
- The company is developing 55+ injectable and ophthalmic products for future filings.
- Caplin Steriles also has approvals across multiple international regulated markets including Australia, Canada, South Africa, UAE, Mexico, and others.
Note:
- The approval further strengthens Caplin Point’s long-term strategy of scaling its sterile injectable and regulated market business globally.
Risk Analysis
Key Risks:
- Pricing pressure in the US generic injectable market.
- Regulatory compliance risks for future inspections and product launches.
- Competition from existing generic manufacturers.
- Commercial ramp-up may take time despite approval.
Worst Case Scenario:
- If pricing competition intensifies or commercialization is delayed, the financial contribution from the approved product could remain limited.
Risk Level: Medium
Company Commentary
- Caplin Steriles stated that the approval strengthens its regulated market injectable portfolio.
- The company highlighted its growing ANDA pipeline and international expansion strategy.
- Management reiterated focus on developing complex injectable and ophthalmic products.
- Caplin Point emphasized its continued investment in regulated market opportunities and manufacturing capabilities.
Official Exchange Filing: Caplin Point Laboratories Limited